Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIV

BACKGROUND: Long-acting subcutaneous lenacapavir (LEN), a first-in-class HIV capsid inhibitor approved by the US FDA for the treatment of multidrug-resistant HIV-1 with twice yearly dosing, is under investigation for HIV-1 pre-exposure prophylaxis (PrEP). We previously derived a simian-tropic HIV-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Swanstrom, Adrienne E., Gorelick, Robert J., Welker, Jorden L., Schmidt, Fabian, Lu, Bing, Wang, Kelly, Rowe, William, Breed, Matthew W., Killoran, Kristin E., Kramer, Joshua A., Donohue, Duncan, Roser, James D., Bieniasz, Paul D., Hatziioannou, Theodora, Pyle, Cathi, Thomas, James A., Trubey, Charles M., Zheng, Jim, Blair, Wade, Yant, Stephen R., Lifson, Jeffrey D., Del Prete, Gregory Q.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470178/
https://www.ncbi.nlm.nih.gov/pubmed/37625266
http://dx.doi.org/10.1016/j.ebiom.2023.104764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470178/
https://www.ncbi.nlm.nih.gov/pubmed/37625266
http://dx.doi.org/10.1016/j.ebiom.2023.104764

Ejemplares similares